GT Biopharma announced the submission of an Investigational New Drug application with the FDA for the development of GTB-3650, a 2nd generation nanobody TriKE for the treatment of patients with CD33+ leukemia, including relapsed/refractory acute myelogenous leukemia and high-risk myelodysplastic syndrome.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GTBP:
- GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia
- GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE® Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
- GT Biopharma presents preclinical data for GTB-5550 for targeted prostate cancer
- GT Biopharma sees cash runway into 2H24
- GT Biopharma reports Q3 EPS (6c) vs. (22c) last year
